Clinical trial
Tipifarnib in Treating Young Patients With Refractory Leukemia
NCT00022451 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00022451 |
|---|---|
| Title | Tipifarnib in Treating Young Patients With Refractory Leukemia |
| Official title | A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients With Refractory Leukemia |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH Children's Oncology Group |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | tipifarnib |
| Start date | Jun 1, 2001 |
| Completion | Mar 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 15, 2012 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: